# Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

> **NCT00642226** · PHASE3 · TERMINATED · sponsor: **Helse Stavanger HF** · enrollment: 34 (actual)

## Conditions studied

- Branch Retinal Vein Occlusion
- Macular Edema

## Interventions

- **PROCEDURE:** Grid Laser
- **PROCEDURE:** Vitrectomy and 20 mg triamcinolone

## Key facts

- **NCT ID:** NCT00642226
- **Lead sponsor:** Helse Stavanger HF
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Due to recruiting problems and the introduction of new treatment strategies (ranibizumab and dexamethasone implant).
- **Last updated:** 2014-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00642226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00642226, "Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00642226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*